UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2016
Commission File Number: 001-37423
Biotie Therapies Oyj
(Exact name of registrant as specified in its charter)
Biotie Therapies Corp.
(Translation of registrant’s name into English)
Joukahaisenkatu 6, FI-20520
Turku, Finland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | x | Form 40-F |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
| Yes | No | x |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
| Yes | No | x |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOTIE THERAPIES CORP. | |||||
| By: | /s/ David Cook | ||||
| Name: | David Cook | ||||
| Title: | Chief Financial Officer | ||||
Date: June 10, 2016
EXHIBIT INDEX
Exhibit Number |
Description |
| 99.1 | Stock Exchange Release dated June 10, 2016 (8:00 a.m. EET): TRUSTEE APPOINTED FOR THE ARBITRATION PROCEEDINGS CONCERNING THE REDEMPTION OF THE MINORITY SHARES IN BIOTIE THERAPIES CORP. |
Exhibit 99.1
| BIOTIE THERAPIES CORP. | STOCK EXCHANGE RELEASE | 10 June 2016, at 8.00 a.m. (EET) |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION OF THIS RELEASE WOULD VIOLATE APPLICABLE REGULATION OR WOULD REQUIRE ADDITIONAL MEASURES IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW.
TRUSTEE APPOINTED FOR THE ARBITRATION PROCEEDINGS CONCERNING THE REDEMPTION OF THE MINORITY SHARES IN BIOTIE THERAPIES CORP.
As previously announced, Acorda Therapeutics, Inc.’s (“Acorda”) intention is to redeem the minority shares in Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V; Nasdaq: BITI) (”Biotie”) by way of arbitration proceedings in accordance with Chapter 18, Section 3 of the Finnish Companies Act to acquire all of the remaining shares in Biotie, including shares represented by American Depositary Shares.
Based on an application filed by Acorda for the aforementioned
arbitration proceedings, the Redemption Committee of the Finland Chamber of Commerce has petitioned the District Court of Finland
Proper for the appointment of a trustee, in accordance with Chapter 18, Section 5 of the Finnish Companies Act, to look after the
interests of Biotie’s minority shareholders in the arbitration proceedings. In its decision, the District Court of Finland
Proper appointed Attorney, MSc (Econ.) Jussi Perho to act as the trustee.
Turku, 10 June 2016
Biotie Therapies Corp.
Timo Veromaa
President and CEO
For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media
INFORMATION REGARDING BIOTIE
Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.
For more information, please visit www.biotie.com.
INFORMATION REGARDING ACORDA
Founded in 1995, Acorda is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders, with its common stock listed on Nasdaq US.
Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, epilepsy, post-stroke walking deficits, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit www.acorda.com.